secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2026-08-06T14:08:06+00:00
Accession:  0001193125-26-337069
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Whitehawk Therapeutics Q2 net loss narrows to $16.6M; cash $190M, runway into 2H 2028
--------------------------------------------------------------------------------

- Net loss of $16.6M for Q2 2026, compared to $52.6M in Q2 2025; R&D expenses fell to $12.9M from $48.8M.
- Cash, equivalents and short-term investments $190.0M at June 30, 2026, up from $145.7M at Dec 31, 2025.
- Completed $87.5M private placement equity financing in May 2026 with existing and new investors.
- Phase 1 trials for HWK-007 and HWK-016 continue enrolling; initial results expected in 1H 2027.
- Entered option agreement with Hangzhou DAC for CPT113 linker-payload and collaboration with Biocytogen for bispecific ADCs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312526337069/0001193125-26-337069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312526337069/whwk-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-337069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer